Microinjections of angiotensin II (Ang II) into the rostral ventrolateral medulla (RVLM) induce a sympathetically-mediated increase in blood pressure (BP), through an interaction with AT 1 -receptors. Under basal conditions in anaesthetised animals, microinjections of AT 1 -receptor antagonists into the RVLM have little, or no effect on BP, suggesting that the angiotensin input to this nucleus is not tonically active. In contrast, microinjections of AT 1 -receptor antagonists into the RVLM of sodium-deplete rats and TGR(mRen2)27 rats, induce a depressor response through sympatho-inhibition. This indicates that when the renin-angiotensin system is activated, angiotensin can act in the RVLM to support sympathetic nerve discharge and BP. This study examined whether angiotensin inputs to the RVLM are activated in the spontaneously hypertensive rat -a pathophysiological model which displays increases in both brain angiotensin levels and sympathetic nerve activity. Bilateral microinjections of the AT 1 -receptor antagonist candesartan cilexetil, (1 nmol in 100 nl), into the RVLM of the spontaneously hypertensive rat induced a significant decrease in lumbar sympathetic nerve discharge (-18±2%) and BP (140±6 to 115±6 mmHg). In contrast, similar microinjections in the Wistar-Kyoto (WKY) rat had no effect on BP or sympathetic nerve discharge. These results are interpreted to suggest that Ang II inputs to the RVLM are activated in the spontaneously hypertensive rat to maintain an elevated level of sympathetic nerve discharge, even in the face of increased BP.
Introduction
The rostral ventrolateral medulla (RVLM) contains a population of bulbospinal, barosensitive neurons, whose activity is essential for the maintenance of tonic sympathetic vasomotor tone and for its reflex regulation. 1 Microinjections of angiotensin II (Ang II) into the RVLM act through AT 1 -receptors to induce a sympathetically-mediated increase in blood pressure (BP). 2, 3 This region is rich in AT 1 -receptors in most species studied, including humans, 4 and contains a plexus of Ang II-like immunoreactive nerve terminals. 5 Consequently, it is considered that Ang II might act in the RVLM as a neurotransmitter or neuromodulator to affect sympathetic nerve discharge (SND) and BP.
Under basal conditions in normotensive, anaes-thetised animals, microinjections of specific AT 1receptor antagonists into the RVLM have little, or no effect on SND and BP, suggesting that Ang II is not tonically released in this nucleus. [6] [7] [8] In contrast to this lack of effect under basal conditions in normal rats, microinjections of AT 1 -receptor antagonists cause decreases in BP and SND in some experimental models. In anaesthetised, sodiumdeplete rats and in conscious TGR(mREN2)27 rats, microinjections of AT 1 -receptor antagonists into the RVLM elicit a decrease in SND and BP. 9, 10 These results indicate that Ang II inputs to the RVLM are inactive under basal conditions, but are activated during sodium depletion and when the brain renin-angiotensin system (RAS) is activated. Many studies point to an involvement of brain Ang II in the increased BP found in experimental models of hypertension, including the spontaneously hypertensive rat (SHR). Central administration of inhibitors of brain Ang II formation or action result in decreases in BP, [11] [12] [13] [14] although these findings are not universal. 15 The mechanism(s) by which brain Ang II might be involved in hypertension are still being elucidated. The brain RAS appears to be activated in the SHR, leading to increased levels of Ang II, at least early in life. [16] [17] [18] In addition, alterations in brain AT 1 -receptor mRNA, 19 AT 1 -receptor 20,21 and receptor affinities have been reported to exist in SHR. 21 These observations have led to the proposal that the increased activity of brain Ang II might be involved in generating, or maintaining, the elevated levels of SND which are observed in the SHR. 22 The purpose of this study was to determine whether Ang II inputs to the RVLM are activated in the SHR and contribute to the elevated level of SND and hence BP.
Methods
All experiments were performed in accordance with the Australian National Health and Medical Research Council code of practice for the care and use of animals for scientific purposes and were approved by the Animal Experimentation Ethics Committee of the Howard Florey Institute. Experiments were performed on aged-matched male SHR or Wistar-Kyoto (WKY) rats (aged: 12-16 weeks; weight: 318-405 g) which were obtained from the Animal Resource Center (Canning Vale, WA, Australia). They were housed in pairs at the Howard Florey Institute for at least one week prior to experimentation and given ad libitum access to standard rat chow and water. Rats were anaesthetised with brietal sodium (80 mg/kg, i.p.), tracheotomised and artificially ventilated with room air, supplemented with oxygen, containing 1.2 to 1.8% isoflurane. The level of isoflurane was adjusted to maintain a deep surgical anaesthesia (total loss of pedal withdrawal and corneal reflexes) throughout the experiment. The animal's temperature was maintained around 37±0.5 o C using a servo-controlled heating blanket (FHC, Brunswick, ME, USA). The left femoral artery and vein were cannulated for measurement of arterial pressure and for intravenous infusions, respectively. Arterial pressure was measured, using a pressure transducer linked to a BP recording device (Stoelting,Wood Dale, IL, USA) which also derived heart rate from the arterial pressure pulse. The animal was then placed in a stereotaxic device (David Kopf Instruments, Tujunga, CA, USA), with the bite bar set at 11.5 mm below the interaural line, and the dorsal surface of the medulla was exposed through the atlanto-occipital membrane. In some animals, lumbar SND was recorded as described previously. 23 Briefly, a branch of the lumbar sympathetic trunk (L3-L5) was isolated through an abdominal incision and placed on a bipolar silver recording electrode. The nerve was cut distally and then covered in a silicone compound (Kwik-Cast, WPI Inc., Sarasota, FL, USA). The signal was amplified (5000 gain), filtered between 100 Hz and 3 kHz, and displayed on an oscilloscope (Hameg GmbH, Frankfurt am Main, Germany). The raw signal was rectified and integrated (10 s time constant) using a Grass model 7P10G integrator (Grass Instrument Division, West Warwick, RI, USA). Both the BP and lumbar sympathetic nerve activity signals were recorded on a video cassette recorder (A.R.Vetter Co., Rebersburg, PA, USA) and also by a MacLab recording device (MacLab 8s, ADInstruments, Sydney, NSW, Australia) for later analysis. After completion of the surgery, the rats were paralysed with pancuronium bromide (1 mg/kg i.v. initially, followed by 0.3 mg/kg supplementary doses). Each time, paralysis was allowed to wear off, and the level of anaesthesia re-assessed before further administration of pancuronium bromide.
All RVLM microinjections were made using glass micropipettes with a tip diameter of 20-40 µm. Initially, the RVLM was mapped using small microinjections (10-20 nl) of 50 mM sodium glutamate. The RVLM was identified as the site where these injections gave a brisk increase in BP and SND. In general, this was located 1.8-2.1 mm lateral to midline, 0.2-0.6 mm rostral to the calamus scriptorius and 3.5-3.8 mm ventral to the dorsal surface of the brainstem. After the RVLM had been identified bilaterally, 100 nl microinjections of 1 mM candesartan were made bilaterally into the RVLM. Histological verification of the injection site was made after the experiment by localisation of rhodamine-labelled microspheres that were included in the candesartan injectate at a 1% dilution. At completion of the experiment, the animals were killed by an overdose of pentobarbital anaesthetic, the brains were removed, placed in 10% formalin and processed to demonstrate the injection site.
Candesartan (a kind gift from AstraZeneca R&D, Mölndal, Sweden) was initially dissolved at a concentration of 10 mM in artificial cerebrospinal fluid (aCSF)(composition in mM: 124 NaCl, 25.6 NaHCO3, 4.9 KCl, 1.2 KH2PO4, 1.3 MgSO4 and 3.1 CaCl2) containing 2.5% of a 1 M solution of Na2CO3 to dissolve the solute. The pH was adjusted to 7.4 and aliquots stored at -20 o C until use. On the day of the experiment, candesartan was diluted to 1mM using aCSF and rhodaminelabelled microspheres. Glutamate (50 mM) was dissolved fresh each day in aCSF.
Control values were obtained from an average of the 60 second period immediately prior to each microinjection except in the cases where insertion of the micropipette into the RVLM caused a brief pressor response. In these cases, the period before insertion of the micropipette was employed. Experimental values were obtained from a mean over 30 seconds, approximately 5-8 minutes after the second injection when the decrease was maximal. Data are expressed as mean±SEM. Responses to candesartan were statistically analysed using a paired t-test to compare the control versus the experimental period within each group.
Results
Baseline arterial pressures were significantly elevated in the SHR (140±6 mmHg) compared with WKY rats (110±5 mmHg) under the same anaesthetic regime and experimental protocol.
To locate the RVLM, microinjections of sodium glutamate (20-40 nl of a 50 mM solution) were made sequentially to each side of the medulla. Microinjections into the RVLM produced a rapid increase in arterial pressure and SND and concomitant decrease in heart rate. Microinjections of candesartan containing rhodamine-labelled beads were then made into this site. Later histological examination of the candesartan injection site showed that such injections were centred below the compact formation of the nucleus ambiguus, at the rostral pole of the inferior olivary nucleus and caudal to the facial nucleus.
Bilateral microinjections of the AT 1 -receptor antagonist, candesartan, into the RVLM of the SHR resulted in a significant decrease in both mean arterial pressure and lumbar SND ( Figure 1 and Table 1 ). The decrease in arterial pressure and lumbar SND reached a maximum 5-10 minutes after the second injection. Thereafter, these parameters returned slowly to baseline levels over the next 30 minutes. No consistent changes in heart rate were observed in response to candesartan in the SHR. In contrast to the SHR, bilateral microinjections of candesartan into the RVLM of the normotensive WKY rats induced no significant change in MAP, heart rate or lumbar SND (Table 1) . 
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Discussion
This study demonstrates that bilateral microinjections of the specific AT 1 -receptor antagonist, candesartan, into the RVLM of the anaesthetised SHR induce a decrease in SND and consequently BP. In contrast, identical microinjections into the RVLM of the anaesthetised WKY have no effect on BP, SND or heart rate. This result is interpreted as demonstration that Ang II inputs to the RVLM are inactive under basal conditions in the normotensive animal but are activated in the hypertensive rat. Such activation leads to an increased level of centrallygenerated sympathetic vasomotor tone in the SHR that would contribute to their elevated BP.
An alternative explanation might be that RVLM neurons in the SHR show an alteration in their responsiveness to Ang II. Several studies have demonstrated increased levels of AT 1 -receptors in the SHR brain. [19] [20] [21] Indeed, RVLM neurons appear to display an increased responsiveness to Ang II in the SHR when compared with the WKY. 24 On the basis of current experimental evidence, it is not possible to distinguish between these hypotheses.
Similar findings of activation of excitatory Ang II inputs to the RVLM have been observed in sodi-um-deplete rats and also in TGR(mREN2)27 rats. 9, 10 Like the SHR, both these experimental animals have an activated RAS and this presumably leads to activation of the inputs to the RVLM. In the sodium-deplete rat, the ability of Ang II in the RVLM to support SND and hence BP makes physiological sense. It is more perplexing that such an action of Ang II occurs in the SHR in the face of already elevated BP.
What is the source of the Ang II input to the RVLM? This question has proved very difficult to answer. Immunohistochemistry has been used to demonstrate a rich plexus of Ang II-like immunoreactive terminals in the region of the RVLM. 5 However, using these anatomical approaches to examine the origin of the Ang II input has proved unsuccessful, as the demonstration of Ang II-like immunoreactivity in neuronal cell bodies is difficult and has not been amenable to combination with retrograde tracing techniques. Physiological studies indicate that, in normotensive animals, activation of neurons in the hypothalamic paraventricular nucleus (PVN) leads to increased levels of SND and BP and that this increase can be attenuated by prior administration of an AT 1 -receptor antagonist into the RVLM. 8 Thus, the PVN may be a source of Ang II inputs to the RVLM. Whether this nucleus is the source of the increased Ang II inputs to the RVLM of the SHR, observed in this study, is not clear. Attempts to bilaterally inhibit the PVN of the SHR resulted in almost total abolition of SND and a dramatic reduction of BP, making it difficult to then test the effect of AT 1 -receptor antagonists in the RVLM on these variables (unpublished observation). Other nuclei which may contain Ang II-like immunoreactive neurons and which project to the RVLM include the lateral parabrachial nucleus, area postrema and nucleus of the solitary tract. 1, 5 Future studies will be required to determine the possible involvement of these nuclei in the activation of RVLM neurons by Ang II in the SHR.
As mentioned above, the PVN may be the source of Ang II inputs to the RVLM. 8 Previous studies have also demonstrated that the PVN may play a role in the generation of hypertension. Specifically, lesions of the PVN in the SHR resulted in normalisation of BP after three weeks, through a reduction in the level of sympathetic tone. 25, 26 In these studies, identical lesions in the normotensive WKY had no long-term effect on BP. In another hypertensive model, the renal-wrap hyperten-PAPER Table 1 Effect of bilateral microinjection of candesartan (1 nmol) into the rostral ventrolateral medulla (RVLM) on mean arterial pressure (MAP), heart rate (HR) and lumbar sympathetic nerve discharge (SND) in the spontaneously hypertensive rat (SHR) and Wistar-Kyoto rat (WKY).
MAP (mmHg) HR (bpm) SND (% change)
Before After Before After
Values given are mean±SEM. * = p<0.01 compared to the relevant control period (paired t-test). sive rat, it has been demonstrated that blockade of GABA A receptors in the PVN has less effect on BP than in the normotensive rat. 27 This indicates that PVN neurons, associated with the regulation of BP, are disinhibited in this hypertensive model, leading to increased levels of SND. Together, these observations suggest that activation of PVN neurons projecting to the RVLM, some of which may employ Ang II as a neuromodulator or neurotransmitter, might be a common feature associated with hypertension. Whilst this study demonstrates that an increased level of Ang II activity in the RVLM contributes to the elevated SND in the SHR, it is clear that this is only one of several abnormalities in neurotransmitter function in this nucleus in these animals. For example, Ito and colleagues have demonstrated that tonic excitatory and inhibitory amino acid mediated inputs to the RVLM are unbalanced in the SHR. 28 A perplexing observation, made by two other laboratories, is that in normotensive animals microinjections of AT 1 -receptor antagonists into the RVLM can induce an increase in SND and BP. 10, 29, 30 In this study, candesartan had no effect on SND or BP when injected bilaterally into the RVLM of the WKY. In a previous study, we also observed no change in BP following bilateral microinjections of candesartan or losartan into the RVLM of the Sprague-Dawley rat or the normotensive rabbit. 7 That an AT 1 antagonist can induce an increase in SND suggests that, if these antagonists are blocking AT 1 -receptors,Ang II can inhibit RVLM neuron activity. No such observations have yet been reported and further studies are required to fully understand these observations.
In conclusion, this study demonstrates that blockade of angiotensin AT 1 -receptors in the RVLM of the SHR significantly reduces both SND and BP. This response is not observed in the normotensive WKY and indicates that increased Ang II activity occurs in this nucleus in the SHR. This promotes an elevated basal vasomotor tone. This observation suggests that a neuronal pathway to the RVLM, which employs Ang II as a transmitter, or modulator, is activated in the SHR. Alternatively, RVLM neurons in the SHR may be more sensitive to Ang II. Either way, aberrant Ang II activity in the RVLM of the SHR appears to contribute to the elevated SND and BP observed in this experimental model of essential hypertension.
